Pascal Deschatelets - 08 May 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Reporting relationship: Chief Scientific Officer
Issuer ticker: APLS
Reported as of: 08 May 2023
Net transaction value: -$1,059,285
SEC form: 4
Accepted by SEC: 09 May 2023, 17:02:50 UTC
Prior SEC filing: 11 Apr 2023
Next SEC filing: 09 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ David Watson, attorney-in-fact for Pascal Deschatelets

Key filing fact

Pascal Deschatelets filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 09 May 2023.

Key facts

This page summarizes Pascal Deschatelets's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 May 2023, 17:02.

Change

Previous filing in this sequence was filed on 11 Apr 2023.
Current net transaction value: -$1,059,285.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APLS transaction

Common Stock

Options Exercise

Transaction value: $49,395
Shares: +18,500
Change %: +1.8%
Price: $2.67^*
Shares after: 1,045,813
Date: 08 May 2023
Ownership: Direct
Footnotes: F1

APLS transaction

Common Stock

Sale

Transaction value: $1,108,680
Shares: -12,000
Change %: -1.1%
Price: $92.39
Shares after: 1,033,813
Date: 08 May 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APLS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -18,500
Change %: -14%
Price: $0.000000
Shares after: 109,994
Date: 08 May 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,500
Exercise price: $2.67
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

This is a scheduled exercise and sale from a 10B5-1 trading plan.

Footnote F2

This stock option was granted on 12/5/2013 and is fully vested.